Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | AOC1 | P19801 | 3/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.32 |
| ▸ | PDE9A | O76083 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | LATS1 | O95835 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21503641 | 0.85 | PDE3B (0.39) | ALDH1A1AOC1AOC3LOXL2MAPT | |
| SCHEMBL805511 | 0.79 | ALDH1A1 (0.45) | ALDH1A1AOC1AOC3LOXL2GPBAR1 | |
| SCHEMBL21503642 | 0.76 | CYP2E1 (0.44) | ALDH1A1AOC1AOC3LIMK1LOXL2 | |
| SCHEMBL24202741 | 0.76 | CYP2E1 (0.39) | AOC1AOC3LOXL2PDE9A | |
| SCHEMBL13003553 | 0.76 | IDO1 (0.46) | ALDH1A1POLB | |
| SCHEMBL28458166 | 0.75 | LOXL2 (0.38) | ALDH1A1AOC1AOC3LOXL2LATS1 | |
| SCHEMBL24973995 | 0.75 | SCD (0.36) | ALDH1A1LIMK1GPBAR1MAPTSCD | |
| SCHEMBL20203184 | 0.75 | AOC1 (0.53) | ALDH1A1AOC1AOC3LOXL2PDE9A | |
| SCHEMBL22166106 | 0.73 | AR (0.39) | ALDH1A1LIMK1LATS1AAK1SLC22A12 | |
| SCHEMBL17318488 | 0.73 | SCN9A (0.40) | ALDH1A1AOC1AOC3LOXL2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | ALDH1A1 569/4885AOC1 2771/4885AOC3 4369/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | ALDH1A1 569/4885AOC1 2771/4885AOC3 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.